Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc.

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

AMVUTTRA Revenue

AMVUTTRA Revenue % Chg.

AMVUTTRA Revenue Common Size

ONPATTRO Revenue

ONPATTRO Revenue % Chg.

ONPATTRO Revenue Common Size

GIVLAARI Revenue

GIVLAARI Revenue % Chg.

GIVLAARI Revenue Common Size

OXLUMO Revenue

OXLUMO Revenue % Chg.

OXLUMO Revenue Common Size

Total Product Revenue

Total Product Revenue % Chg.

Total Product Revenue Common Size

Roche - Collaboration Revenue

Roche - Collaboration Revenue % Chg.

Roche - Collaboration Revenue Common Size

Regeneron Pharmaceuticals - Collaboration Revenue

Regeneron Pharmaceuticals - Collaboration Revenue % Chg.

Regeneron Pharmaceuticals - Collaboration Revenue Common Size

Novartis AG - Collaboration Revenue

Novartis AG - Collaboration Revenue % Chg.

Novartis AG - Collaboration Revenue Common Size

Vir Biotechnology - Collaboration Revenue

Vir Biotechnology - Collaboration Revenue % Chg.

Vir Biotechnology - Collaboration Revenue Common Size

Other - Collaboration Revenue (Pre-FY2023)

Other - Collaboration Revenue (Pre-FY2023) % Chg.

Other - Collaboration Revenue (Pre-FY2023) Common Size

Other - Collaboration Revenue (Post-FY2022)

Other - Collaboration Revenue (Post-FY2022) % Chg.

Other - Collaboration Revenue (Post-FY2022) Common Size

Total Collaboration Revenue

Total Collaboration Revenue % Chg.

Total Collaboration Revenue Common Size

Royalty Revenue

Royalty Revenue % Chg.

Royalty Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Revenue	Sep '25	Jun '25
AMVUTTRA Revenue	685.3	492
ONPATTRO Revenue	39.1	52.5
GIVLAARI Revenue	73.9	80.8
OXLUMO Revenue	52.8	46.9
Total Product Revenue	851.1	672.2
Roche - Collaboration Revenue	326.6	18.3
Regeneron Pharmaceuticals - Collaboration Revenue	22.5	32.5
Novartis AG - Collaboration Revenue	—	—
Vir Biotechnology - Collaboration Revenue	—	—
Other - Collaboration Revenue (Pre-FY2023)	—	—
Other - Collaboration Revenue (Post-FY2022)	2.6	10.7
Total Collaboration Revenue	351.7	61.5
Royalty Revenue	46.2	40
Total Revenue	1,249	773.7